260 related articles for article (PubMed ID: 24962661)
1. Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression--introducing a novel prognostic model for bladder cancer recurrence.
Rausch S; Hennenlotter J; Todenhöfer T; Aufderklamm S; Schwentner C; Sievert KD; Stenzl A; Gakis G
Urol Oncol; 2014 Nov; 32(8):1178-83. PubMed ID: 24962661
[TBL] [Abstract][Full Text] [Related]
2. Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer.
Li CE; Chien CS; Chuang YC; Chang YI; Tang HP; Kang CH
Int Urol Nephrol; 2016 Jun; 48(6):993-9. PubMed ID: 26995008
[TBL] [Abstract][Full Text] [Related]
3. Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m
Blute ML; Kucherov V; Rushmer TJ; Damodaran S; Shi F; Abel EJ; Jarrard DF; Richards KA; Messing EM; Downs TM
BJU Int; 2017 Sep; 120(3):387-393. PubMed ID: 28464520
[TBL] [Abstract][Full Text] [Related]
4. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
5. Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.
Kobatake K; Hayashi T; Black PC; Goto K; Sentani K; Kaneko M; Yasui W; Mita K; Teishima J; Matsubara A
Int J Urol; 2017 Aug; 24(8):594-600. PubMed ID: 28734027
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
Mano R; Baniel J; Shoshany O; Margel D; Bar-On T; Nativ O; Rubinstein J; Halachmi S
Urol Oncol; 2015 Feb; 33(2):67.e1-7. PubMed ID: 25060672
[TBL] [Abstract][Full Text] [Related]
7. Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value.
Fang D; Zhang L; Li X; Yu W; Singla N; Zhao G; Xiong G; Song Y; He Q; He Z; Zhou L
Ann Surg Oncol; 2015 Aug; 22(8):2789-98. PubMed ID: 25564161
[TBL] [Abstract][Full Text] [Related]
8. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
10. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
[TBL] [Abstract][Full Text] [Related]
11. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
12. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
13. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.
Kobayashi S; Fujii Y; Koga F; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
Urol Oncol; 2014 Jan; 32(1):38.e29-36. PubMed ID: 23702087
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
[TBL] [Abstract][Full Text] [Related]
15. Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer.
Soria F; Moschini M; Abufaraj M; Wirth GJ; Foerster B; Gust KM; Özsoy M; Briganti A; Gontero P; Mathieu R; Rouprêt M; Karakiewicz PI; Shariat SF
Urol Oncol; 2017 Mar; 35(3):113.e9-113.e14. PubMed ID: 27908681
[TBL] [Abstract][Full Text] [Related]
16. Prediction of recurrence in non-muscle invasive bladder cancer patients. Do patient characteristics matter?
Ucpinar B; Erbin A; Ayranci A; Caglar U; Alis D; Basal S; Sarilar O; Akbulut MF
J BUON; 2019; 24(4):1659-1665. PubMed ID: 31646822
[TBL] [Abstract][Full Text] [Related]
17. Is urinary soluble Fas an independent predictor of non-muscle-invasive bladder cancer? A prospective chart study.
Yang H; Li H; Wang Z; Gao J; Guo Y
Urol Int; 2013; 91(4):456-61. PubMed ID: 23948854
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of 'high-grade' Ta bladder cancers according to the WHO 2004 classification: are these equivalent to 'high-risk' non-muscle-invasive bladder cancer?
Gontero P; Gillo A; Fiorito C; Oderda M; Pacchioni D; Casetta G; Peraldo F; Zitella A; Tizzani A; Ricceri F
Urol Int; 2014; 92(2):136-42. PubMed ID: 24080613
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34.
Ajili F; Kacem M; Tounsi H; Darouiche A; Enayfer E; Chebi M; Manai M; Boubaker S
Ultrastruct Pathol; 2012 Oct; 36(5):336-42. PubMed ID: 22574784
[TBL] [Abstract][Full Text] [Related]
20. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer.
Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Fajkovic H; Babjuk M; Kautzky-Willer A; Bachmann A; Scherr DS; Shariat SF
BJU Int; 2013 Dec; 112(8):1105-12. PubMed ID: 24053906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
